Pre-screening to match ovarian cancer tumor samples with investigational cancer drugs

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational pre-screening protocol collects patients' archival or metastatic FFPE tumor tissue to run the Drug Response Predictor (DRP®) developed by Allarity Therapeutics. The DRP® output is used to identify whether specimens show predicted sensitivity to investigational agents available through the sponsor and to compare predicted sensitivity with prior chemotherapy responses in retrospective analyses. Eligible participants generally have epithelial ovarian cancer that is platinum-resistant or platinum-ineligible and have available FFPE tissue; platinum-refractory patients are excluded. The program is conducted at multiple U.S. cancer centers and is intended to generate data to guide future treatment decisions and prospective testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histological confirmed epithelia ovarian cancer
* Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
* Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
* FFPE tumor tissue available

Exclusion Criteria:

* Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
* Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

Where it's running

• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• Emory Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting
• University of New Mexico Comprehensive Cancer
  Albuquerque, New Mexico, United States Recruiting
• The Blavatnik Family-Chelsea Medical Center at Mount Sinai
  New York, New York, United States Recruiting
• OU Health Stephenson Cancer Center
  Oklahoma City, Oklahoma, United States Recruiting
• University Medical Center Cancer Center
  Lubbock, Texas, United States Recruiting

Study contacts

• Study coordinator: US: Kathleen Moore
• Email: KathleenMoore@ouhealth.com
• Phone: +1 405-271-8707

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• EHR-based approach to boost HBOC genetic testing in at-risk women

  A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.

  Recruiting Columbia University · New York, New York · NCT07876349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.